Jump to Main Content
Efficacy of clade 2.3.2 H5 commercial vaccines in protecting chickens from clade 188.8.131.52 H5N8 highly pathogenic avian influenza infection
- Yuk, Seong-su, Erdene-Ochir, T.O., Kwon, Jung-Hoon, Noh, Jin-Yong, Hong, Woo-tack, Jeong, Jei-Hyun, Jeong, Sol, Gwon, Gyeong-Bin, Shin, Jong-il, Sur, Jung-Hyang, Song, Chang-Seon
- Vaccine 2017 v.35 no.9 pp. 1316-1322
- Influenza A virus, avian influenza, chickens, death, histology, migratory birds, monitoring, mortality, vaccination, vaccines, viral shedding, viruses, wild birds, China, Germany, Italy, Netherlands, South Korea, United Kingdom, United States
- Emerging clade 184.108.40.206 of the highly pathogenic avian influenza (HPAI) virus strain H5N8, which had been detected sporadically in domestic poultry in China, started to affect wild birds and poultry in South Korea in 2014. The virus was spread to Germany, Italy, the Netherlands, United Kingdom, and even United States by migratory birds. Here, we tested currently used commercial clade 2.3.2 H5 vaccines to evaluate mortality, clinical signs, virus shedding, and histological damage after experimental infection of chickens with the clade 220.127.116.11 HPAI H5N8 virus. Although the vaccination protected chickens from death, it failed to prevent chickens from shedding the virus and from tissue damage according to histological examination. These results suggest that the use of appropriate vaccines that match the currently epidemic HPAI virus is recommended, and continuous HPAI surveillance and testing of currently used commercial vaccines should be performed.